TRUVADA™

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIVHIV Infection

Phase 3

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

TerminatedNCT00745823

Merck Sharp & Dohme LLCHIV

Start: 2008-09-30End: 2011-05-31Updated: 2017-03-21

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

CompletedNCT02131233

Merck Sharp & Dohme LLCHIV Infection

Start: 2014-05-23End: 2016-12-19Updated: 2019-01-30

Related Papers

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

2017-09-1120 citations

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

2011-09-18140 citations